A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577

Standard

A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. / Pape, Marieke; Vissers, Pauline A. J.; Beerepoot, Laurens V. et al.

In: Therapeutic advances in medical oncology, Vol. 14, 01.02.2022.

Research output: Contribution to journal › Article › Academic › peer-review

Author

Pape, Marieke ; Vissers, Pauline A. J. ; Beerepoot, Laurens V. et al. / A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577. In: Therapeutic advances in medical oncology. 2022 ; Vol. 14.

BibTeX

@article{866cf89af2e84f77891a4b09b503cd39,

title = "A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577",

abstract = "Background: Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). Population-based data can provide insights in outcomes from clinical practice. The aim of our study was to investigate disease-free and overall survival in a nationwide population aligned with the inclusion criteria of CheckMate 577. Patients and Methods: Resected patients with stage II/III esophageal or gastroesophageal junction cancer (2015–2016) treated with neoadjuvant chemoradiotherapy were selected from the Netherlands Cancer Registry. Patients with cervical esophageal cancer, irradical resection, or complete pathological response were excluded. Disease-free and overall survival were assessed from 12 weeks after resection using Kaplan-Meier methods. In addition, to adjust for differences in characteristics between CheckMate 577 and our population-based cohort, a matching-adjusted indirect comparison was performed for pathological lymph node status and pathological tumor status. Results: We identified 634 patients. Sixty percent of patients were diagnosed with recurrence or were deceased at the end of follow-up. Median disease-free survival was 19.7 months and median overall survival was 32.2 months. After the matching procedure, the median disease-free survival was 17.2 months and median overall survival was 28.2 months. Conclusions: Disease-free survival in our population-based study was considerably longer than the placebo population of CheckMate-577 (19.7 versus 11.0 months). Possible explanations are differences in characteristics, quality of esophageal cancer care, or differential strategies for evaluation of recurrence. In the Netherlands postoperative imaging is not part of the standard follow-up as opposed to the standard postoperative imaging in the CheckMate 577 trial. The difference in postoperative imaging could partially explain the longer disease-free survival observed in our study. Quality and optimization of current treatment modalities remain important aspects of esophageal cancer care.",

keywords = "disease-free survival, esophageal cancer, gastroesophageal junction cancer, population-based",

author = "Marieke Pape and Vissers, {Pauline A. J.} and Beerepoot, {Laurens V.} and {van Berge Henegouwen}, {Mark I.} and Lagarde, {Sjoerd M.} and Stella Mook and Markus Moehler and {van Laarhoven}, {Hanneke W. M.} and Verhoeven, {Rob H. A.}",

note = "Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry. The authors thank all participating hospitals in the Netherlands. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bristol Myers Squibb (CA209-77E). The funder has financed part of the data collection. The funder had no role in the design of the study, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bristol Myers Squibb (CA209-77E). The funder has financed part of the data collection. The funder had no role in the design of the study, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study. Publisher Copyright: {\textcopyright} The Author(s), 2022.",

year = "2022",

month = feb,

day = "1",

doi = "10.1177/17588359221075495",

language = "English",

volume = "14",

journal = "Therapeutic advances in medical oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

RIS

TY - JOUR

T1 - A population-based study in resected esophageal or gastroesophageal junction cancer aligned with CheckMate 577

AU - Pape, Marieke

AU - Vissers, Pauline A. J.

AU - Beerepoot, Laurens V.

AU - van Berge Henegouwen, Mark I.

AU - Lagarde, Sjoerd M.

AU - Mook, Stella

AU - Moehler, Markus

AU - van Laarhoven, Hanneke W. M.

AU - Verhoeven, Rob H. A.

N1 - Funding Information: The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry. The authors thank all participating hospitals in the Netherlands. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bristol Myers Squibb (CA209-77E). The funder has financed part of the data collection. The funder had no role in the design of the study, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study. Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Bristol Myers Squibb (CA209-77E). The funder has financed part of the data collection. The funder had no role in the design of the study, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The corresponding author had full access to all the data in the study. Publisher Copyright: © The Author(s), 2022.

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Background: Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). Population-based data can provide insights in outcomes from clinical practice. The aim of our study was to investigate disease-free and overall survival in a nationwide population aligned with the inclusion criteria of CheckMate 577. Patients and Methods: Resected patients with stage II/III esophageal or gastroesophageal junction cancer (2015–2016) treated with neoadjuvant chemoradiotherapy were selected from the Netherlands Cancer Registry. Patients with cervical esophageal cancer, irradical resection, or complete pathological response were excluded. Disease-free and overall survival were assessed from 12 weeks after resection using Kaplan-Meier methods. In addition, to adjust for differences in characteristics between CheckMate 577 and our population-based cohort, a matching-adjusted indirect comparison was performed for pathological lymph node status and pathological tumor status. Results: We identified 634 patients. Sixty percent of patients were diagnosed with recurrence or were deceased at the end of follow-up. Median disease-free survival was 19.7 months and median overall survival was 32.2 months. After the matching procedure, the median disease-free survival was 17.2 months and median overall survival was 28.2 months. Conclusions: Disease-free survival in our population-based study was considerably longer than the placebo population of CheckMate-577 (19.7 versus 11.0 months). Possible explanations are differences in characteristics, quality of esophageal cancer care, or differential strategies for evaluation of recurrence. In the Netherlands postoperative imaging is not part of the standard follow-up as opposed to the standard postoperative imaging in the CheckMate 577 trial. The difference in postoperative imaging could partially explain the longer disease-free survival observed in our study. Quality and optimization of current treatment modalities remain important aspects of esophageal cancer care.

AB - Background: Results of CheckMate 577 show an improved disease-free survival for patients with resected esophageal or gastroesophageal junction cancer treated with adjuvant nivolumab compared with placebo (22.4 versus 11.0 months). Population-based data can provide insights in outcomes from clinical practice. The aim of our study was to investigate disease-free and overall survival in a nationwide population aligned with the inclusion criteria of CheckMate 577. Patients and Methods: Resected patients with stage II/III esophageal or gastroesophageal junction cancer (2015–2016) treated with neoadjuvant chemoradiotherapy were selected from the Netherlands Cancer Registry. Patients with cervical esophageal cancer, irradical resection, or complete pathological response were excluded. Disease-free and overall survival were assessed from 12 weeks after resection using Kaplan-Meier methods. In addition, to adjust for differences in characteristics between CheckMate 577 and our population-based cohort, a matching-adjusted indirect comparison was performed for pathological lymph node status and pathological tumor status. Results: We identified 634 patients. Sixty percent of patients were diagnosed with recurrence or were deceased at the end of follow-up. Median disease-free survival was 19.7 months and median overall survival was 32.2 months. After the matching procedure, the median disease-free survival was 17.2 months and median overall survival was 28.2 months. Conclusions: Disease-free survival in our population-based study was considerably longer than the placebo population of CheckMate-577 (19.7 versus 11.0 months). Possible explanations are differences in characteristics, quality of esophageal cancer care, or differential strategies for evaluation of recurrence. In the Netherlands postoperative imaging is not part of the standard follow-up as opposed to the standard postoperative imaging in the CheckMate 577 trial. The difference in postoperative imaging could partially explain the longer disease-free survival observed in our study. Quality and optimization of current treatment modalities remain important aspects of esophageal cancer care.

KW - disease-free survival

KW - esophageal cancer

KW - gastroesophageal junction cancer

KW - population-based

UR - http://www.scopus.com/inward/record.url?scp=85125849862&partnerID=8YFLogxK

U2 - 10.1177/17588359221075495

DO - 10.1177/17588359221075495

M3 - Article

C2 - 35237351

VL - 14

JO - Therapeutic advances in medical oncology

JF - Therapeutic advances in medical oncology

SN - 1758-8340

ER -

ID: 22156305

Generic Portal